The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
Open accessAbstract
Immune checkpoint inhibitors (ICIs) with nivolumab and pembrolizumab are promising agents for advanced hepatocellular carcinoma (HCC) but lack of effective biomarkers. We aimed to investigate the potential predictors of response and factors associated with overall survival (OS) for ICI treatment in unresectable HCC patients. Ninety-five patients who received nivolumab or pembrolizumab for unresectable HCC were enrolled for analyses. Radiologic evaluation was based on RECIST v1.1. Factors associated with outcomes were analyzed. Of 90 patients with evaluable images, the objective response rate (ORR) was 24.4%. Patients at Child–Pugh A or received combination treatment had higher ORR. Early alpha-fetoprotein (AFP) >10% reduction (within 4 weeks) was the only independent predictor of best objective response (odds ratio: 7.259, p = 0.001). For patients with baseline AFP ≥10 ng/mL, significantly higher ORR (63.6% vs. 10.2%, p < 0.001) and disease control rate (81.8% vs. 14.3%, p < 0.001) were observed in those with early AFP reduction than those without. In addition, early AFP reduction and albumin-bilirubin (ALBI) grade or Child–Pugh class were independent factors associated with OS in different models. In conclusion, a 10-10 rule of early AFP response can predict objective response and survival to ICI treatment in unresectable HCC. ALBI grade and Child–Pugh class determines survival by ICI treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2017) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,107
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M. J., Reeves, H. L., O’Beirne, J. P., Fox, R., Skowrońska, A., Palmer, D. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9151 · Cited by 2,865
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
Caldéraro, J., Rousseau, B., Amaddeo, G., Mercey-Ressejac, M., Charpy, C., Costentin, C. E., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., et al. (2016) · Hepatology · doi:10.1002/hep.28710 · Cited by 448
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Yau, T. C. C., Hsu, C., Kim, T., Choo, S.-P., Kang, Y., Hou, M., Numata, K., Yeo, W., Chopra, A., Ikeda, M., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.014 · Cited by 267
Self-citationReig, M., Rimola, J., Torres, F., Darnell, A., de Lope, C. R., Forner, A., Llarch, N., Ríos, J., Ayuso, C., & Bruix, J. (2013) · Hepatology · doi:10.1002/hep.26586 · Cited by 257
Yau, T. C. C., Kang, Y., Kim, T., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M., Matilla, A. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4012 · Cited by 229
Self-citationFinn, R. S., Ryoo, B., Merle, P., Kudo, M., Bouattour, M., Lim, H.-Y., Breder, V. V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4004 · Cited by 204
Self-citationLiu, P., Hsu, C., Hsia, C., Lee, Y.-H., Chiou, Y., Huang, Y., Lee, F., Lin, H., Hou, M., & Huo, T. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13608 · Cited by 176
Self-citationShao, Y., Lin, Z., Hsu, C., Shen, Y., Hsu, C.-H., & Cheng, A. (2010) · Cancer · doi:10.1002/cncr.25257 · Cited by 172
Nivolumab for the treatment of hepatocellular carcinoma
Finkelmeier, F., Waidmann, O., & Trojan, J. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1535315 · Cited by 170
Khunger, M., Hernández, A. V., Pasupuleti, V., Rakshit, S., Pennell, N. A., Stevenson, J. P., Mukhopadhyay, S., Schalper, K. A., & Velcheti, V. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00030 · Cited by 158
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Kudo, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i7.789 · Cited by 145
Iavarone, M. A., Cabibbo, G., Biolato, M., Corte, C. D., Maida, M. F., Barbàra, M., Basso, M., Vavassori, S., Craxı̀, A., Grieco, A., et al. (2015) · Hepatology · doi:10.1002/hep.27729 · Cited by 130
Scheiner, B., Kirstein, M. M., Hucke, F., Finkelmeier, F., Schulze, K., von Felden, J., Koch, S., Schwabl, P., Hinrichs, J. B., Waneck, F., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15245 · Cited by 128
Ikeda, M., Sung, M. W., Kudo, M., Kobayashi, M., Baron, A. D., Finn, R. S., Kaneko, S., Zhu, A. X., Kubota, T., Kraljevic, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4076 · Cited by 125
Stein, S., Pishvaian, M. J., Lee, M. S., Lee, K.-H., Hernandez, S., Kwan, A., Liu, B., Grossman, W., Iizuka, K., & Ryoo, B. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4074 · Cited by 111
Cabibbo, G., Petta, S., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E. G., Negrini, G., Ciccarese, F., Rapaccini, G. L., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.033 · Cited by 110
Mehta, N. J., Dodge, J. L., Roberts, J. P., Hirose, R., & Yao, F. Y. (2018) · Hepatology · doi:10.1002/hep.30413 · Cited by 109
Shao, Y., Liu, T., Hsu, C., Lu, L., Shen, Y., Lin, Z., Cheng, A., & Hsu, C. (2019) · Liver International · doi:10.1111/liv.14210 · Cited by 107
Kambhampati, S., Bauer, K., Bracci, P. M., Keenan, B. P., Behr, S. C., Gordan, J. D., & Kelley, R. K. (2019) · Cancer · doi:10.1002/cncr.32206 · Cited by 104
Kudo, M., Matilla, A. M., Santoro, A., Melero, I., Gracián, A. C., Acosta-Rivera, M., Choo, S. P., El-Khoueiry, A. B., Kuromatsu, R., El‐Rayes, B. F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.327 · Cited by 98
Memon, K., Kulik, L., Lewandowski, R. J., Wang, E., Ryu, R. K., Riaz, A., Nikolaidis, P., Miller, F. H., Yaghmai, V., Baker, T., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.020 · Cited by 95
Finkelmeier, F., Czauderna, C., Perkhofer, L., Ettrich, T. J., Trojan, J., Weinmann, A., Marquardt, J. U., Vermehren, J., & Waidmann, O. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2780-8 · Cited by 44
Pinato, D. J., Yen, C., Bettinger, D., Ramaswami, R., Arizumi, T., Ward, C. E., Pirisi, M., Burlone, M. E., Thimme, R., Kudo, M., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13904 · Cited by 44
Lee, P., Chen, Y., Chao, Y., Huo, T., Li, C., Su, C., Lee, M., Hou, M., Lee, F., Lin, H., et al. (2017) · Liver International · doi:10.1111/liv.13527 · Cited by 44
Self-citationJung, J., Yoon, S. M., Han, S., Shim, J. H., Kim, K. M., Lim, Y., Lee, H. C., Kim, S. Y., Park, J., & Kim, J. H. (2015) · BMC Cancer · doi:10.1186/s12885-015-2017-z · Cited by 17
Meyer, T., Melero, I., Yau, T., Hsu, C., Kudo, M., Choo, S. P., Trojan, J., Welling, T. H., Kang, Y.-K., Yeo, W., et al. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30249-6 · Cited by 10
Cited by
Sorted by citations
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
Demirtaş, C. Ö., D’Alessio, A., Rimassa, L., Sharma, R., & Pinato, D. J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100347 · Cited by 230
Lee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004779 · Cited by 217
Self-citationShao, Y., Wang, S.-Y., Lin, S., Chen, K.-Y., Tseng, J., Ho, M., Lee, R., Liang, P., Liao, L., Huang, K., et al. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.10.031 · Cited by 114
Self-citationProgress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 94
Metadata
- Authors
- Lee, P.-C., Chao, Y., Chen, M.-H., Lan, K.-H., Lee, C.-J., Lee, I.-C., Chen, S.-C., Hou, M.-C., & Huang, Y.-H.
- Affiliations
- Taipei Veterans General Hospital (TW)
- Corresponding author
- Chao, Yee
- Huang, Yi-Hsiang
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-01-11
- Volume
- 12
- Issue
- 1
- Pages
- 182
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7017111
- OpenAlex
- W2999675465
- Cited by
- 105
- References
- 42
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 10 · 2023: 21 · 2022: 27 · 2021: 20 · 2020: 12
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (MOST108-2628-B075-006, MOST 108-)
- Taipei Veterans General Hospital (V109C‐048)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- hepatocellular carcinoma, immune checkpoint inhibitors, nivolumab, pembrolizumab, predictive biomarkers, alpha-fetoprotein, objective response rate, overall survival, albumin-bilirubin grade, Child-Pugh score, combination therapy, RECIST 1.1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
